Bruno Cassinat
Overview
Explore the profile of Bruno Cassinat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
2245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Salit R, et al.
Blood Adv
. 2024 Nov;
9(4):797-807.
PMID: 39561372
The aim of our study was to analyze the potential survival benefit associated with hematopoietic stem cell transplantation (HSCT) according to clinicobiological scores, which incorporate mutation-enhanced international prognostic score system...
2.
Ganesan S, Awan-Toor S, Guidez F, Maslah N, Rahimy R, Aoun C, et al.
JCI Insight
. 2024 Oct;
9(23).
PMID: 39470742
Despite the advances in the understanding and treatment of myeloproliferative neoplasm (MPN), the disease remains incurable with the risk of evolution to acute myeloid leukemia or myelofibrosis (MF). Unfortunately, the...
3.
Aoun C, Maslah N, Ganesan S, Salomao N, Gendron R, Awan Toor S, et al.
J Cell Mol Med
. 2024 Oct;
28(20):e70138.
PMID: 39431551
Myeloproliferative neoplasms (MPNs) are characterized by an increased production of blood cells due to the acquisition of mutations such as JAK2. TGF-β, whose secretion is increased in MPN patients, is...
4.
Wang Y, Wei C, Lin C, Gurnari C, Awada H, Benajiba L, et al.
Leukemia
. 2024 Oct;
39(1):144-154.
PMID: 39367172
In addition to high-molecular risk (HMR) mutations (ASXL1, EZH2, SRSF2, IDH, and U2AF1), lower JAK2V617F variant allele frequencies (VAF) have been demonstrated to be associated with poor prognosis of myelofibrosis...
5.
Hei Z, Yang S, Ouyang G, Hanna J, Lepoivre M, Huynh T, et al.
Br J Haematol
. 2024 Aug;
205(3):1017-1030.
PMID: 39087522
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by complex molecular and cytogenetic abnormalities. Pro-oxidant cellular redox status is a common hallmark of AML cells, providing a rationale for...
6.
Maslah N, Rety S, Bonnamy M, Aguinaga L, Huynh T, Parietti V, et al.
Leukemia
. 2024 May;
38(7):1630-1633.
PMID: 38777834
No abstract available.
7.
Rathje K, Gagelmann N, Salit R, Schroeder T, Gurnari C, Pagliuca S, et al.
Bone Marrow Transplant
. 2024 May;
59(8):1154-1160.
PMID: 38773281
Acute and chronic graft-versus-host disease (GvHD) are major complications of allogeneic hematopoietic cell transplantation (alloHCT). In vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG) as part of the conditioning regimen prior...
8.
Bourrienne M, Le Cam Duchez V, Faille D, Farkh C, Solo Nomenjanahary M, Gay J, et al.
Blood Adv
. 2024 Feb;
8(12):3330-3343.
PMID: 38386979
Cerebral venous sinus thrombosis (CVST) is an uncommon venous thromboembolic event accounting for <1% of strokes resulting in brain parenchymal injuries. JAK2V617F mutation, the most frequent driving mutation of myeloproliferative...
9.
Guerra M, Pasquer H, Daltro de Oliveira R, Soret-Dulphy J, Maslah N, Zhao L, et al.
Am J Hematol
. 2024 Jan;
99(4):741-744.
PMID: 38279562
Comparative clinical characteristics, molecular landscape and prognosis scoring for primary (PMF) and secondary myelofibrosis (SMF).
10.
Gou P, Liu D, Ganesan S, Lauret E, Maslah N, Parietti V, et al.
Blood Cancer J
. 2024 Jan;
14(1):1.
PMID: 38177095
Classical myeloproliferative neoplasms (MPNs) are characterized by the proliferation of myeloid cells and the risk of transformation into myelofibrosis or acute myeloid leukemia (AML) and TP53 mutations in MPN patients...